Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium oxybate - Avadel Pharmaceuticals

Next Previous
X
Search
Drug Profile

Sodium oxybate - Avadel Pharmaceuticals

Alternative Names: FT-218; LUMRYZ; Micropump® sodium oxybate; ON-SXB

Latest Information Update: 06 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Flamel Technologies
  • Developer Avadel Pharmaceuticals
  • Class Butyric acids; Hydroxybutyrates; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Narcolepsy
  • Phase III Idiopathic hypersomnia

Most Recent Events

  • 31 Oct 2024 US District Court for the District of Columbia rules in favour of FDA in a suit brought by Jazz Pharmaceuticals regarding the FDA’s approval of LUMRYZ™ for Narcolepsy
  • 16 Oct 2024 Registered for Narcolepsy (In children) in USA (PO)
  • 31 Jul 2024 Phase-III clinical trials in Idiopathic hypersomnia (Treatment-experienced) in USA (PO) (NCT06525077)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top